Atria Wealth Solutions’s Sarepta Therapeutics SRPT Stock Holding History

Atria Wealth Solutions’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,740	Closed	-$558K	–	1869
2025 Q1	$558K	Sell	8,740 -2,952	-25%	-$311K	0.01%	1152
2024 Q4	$1.42M	Buy	11,692 +1,108	+10%	+$136K	0.02%	778
2024 Q3	$1.32M	Sell	10,584 -325	-3%	-$44.9K	0.01%	815
2024 Q2	$1.72M	Sell	10,909 -300	-3%	-$38.5K	0.02%	680
2024 Q1	$1.45M	Sell	11,209 -1,550	-12%	-$190K	0.02%	748
2023 Q4	$1.23M	Buy	12,759 +665	+5%	+$63.8K	0.02%	783
2023 Q3	$1.47M	Sell	12,094 -421	-3%	-$47.6K	0.02%	665
2023 Q2	$1.43M	Sell	12,515 -1,438	-10%	-$185K	0.02%	696
2023 Q1	$1.92M	Sell	13,953 -1,682	-11%	-$218K	0.03%	551
2022 Q4	$2.03M	Buy	15,635 +1,618	+12%	+$187K	0.03%	510
2022 Q3	$1.55M	Sell	14,017 -1,105	-7%	-$111K	0.03%	569
2022 Q2	$1.13M	Buy	15,122 +1,641	+12%	+$121K	0.02%	647
2022 Q1	$1.05M	Buy	+13,481	New	+$1.03M	0.02%	708

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Atria Wealth Solutions's SRPT Position: Q2 2025 in Review

Atria Wealth Solutions sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 8,740 shares — an estimated $558K sold.

Atria Wealth Solutions first reported a position in SRPT in Q1 2022 and held it in 13 quarters. The position peaked at $2.03M in Q4 2022. 363 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Atria Wealth Solutions reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Atria Wealth Solutions sold 8,740 Sarepta Therapeutics shares in Q2 2025, an estimated $558K.
Atria Wealth Solutions first reported a position in Sarepta Therapeutics in Q1 2022 and held it in 13 quarters.
Atria Wealth Solutions's Sarepta Therapeutics position peaked at $2.03M in Q4 2022.
363 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Atria Wealth Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.